The American Society of Clinical Oncology (ASCO) Annual Meeting is a pivotal event for oncology professionals, and ASCO 2025, happening from May 31 to June 2, is no exception. In this OncologyTube exclusive video, we’re counting down the Top 10 breast cancer trials you won’t want to miss. From groundbreaking therapies to long-term updates, these presentations will shape the future of breast cancer treatment. Let’s dive in!
10. NeoSTAR Trial
Presentation: June 1, 8:12 AM
The NeoSTAR trial evaluates neoadjuvant sacituzumab govitecan (Trodelvy) combined with pembrolizumab (Keytruda) in early triple-negative breast cancer (TNBC). This study could redefine early-stage TNBC treatment strategies.
9. NRG-BR003
Presentation: May 31, 8:00 AM
A late-breaking trial, NRG-BR003 examines the role of carboplatin in node-positive or high-risk TNBC. This session offers critical insights into improving outcomes for high-risk patients.
8. MA.40/FINER Trial
Presentation: May 31, 2:31 PM
This late-breaking study tests fulvestrant (Faslodex) with ipatasertib following CDK4/6 inhibitor therapy in advanced breast cancer. It’s a must-watch for those focused on hormone receptor-positive (HR+) breast cancer.
7. VERITAC-2
Presentation: May 31, 1:15 PM
VERITAC-2 compares vepdegestrant (a PROTAC therapy) to fulvestrant in HR+ metastatic breast cancer. This late-breaking trial could introduce a new therapeutic option for metastatic cases.
6. Oral Paclitaxel (DHP107) vs IV Paclitaxel
Presentation: May 31, 3:11 PM
The DHP107 trial compares oral paclitaxel to IV paclitaxel for breast cancer patients. This study could simplify administration and improve patient quality of life.
5. SOFT + TEXT 15-Year Update
Presentation: June 2, 4:48 PM
This trial provides long-term data on ovarian function suppression in younger breast cancer patients. It’s a critical update for managing premenopausal breast cancer cases.
4. neoCARHP Trial
Presentation: June 2, 3:00 PM
A late-breaking trial, neoCARHP studies chemotherapy de-escalation in HER2-positive early breast cancer. This could lead to less toxic treatment regimens without compromising efficacy.
3. SERENA-6
Presentation: June 1, 1:00 PM
SERENA-6 tests camizestrant with CDK4/6 inhibitors in ESR1-mutated HR+ advanced breast cancer. This late-breaking study is poised to impact treatment for ESR1-mutated cases.
2. ASCENT-04/KEYNOTE-D19
Presentation: May 31, 3:35 PM
This late-breaking trial compares sacituzumab govitecan plus pembrolizumab to chemotherapy plus pembrolizumab in first-line TNBC. It’s a head-to-head comparison with major implications for TNBC care.
1. DESTINY-Breast09
Presentation: June 2, 7:30 AM
Topping our list, DESTINY-Breast09 compares T-DXd (Enhertu) plus pertuzumab (Perjeta) to THP in first-line HER2-positive metastatic breast cancer. This late-breaking study could set a new standard for HER2-positive treatment.
Go Here to Double Check Dates and Times as They May Have Changed: https://meetings.asco.org/abstracts-presentations
